<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Caroline H Karugu</style></author><author><style face="normal" font="default" size="100%">Charles Agyemang</style></author><author><style face="normal" font="default" size="100%">Ilboudo, Patrick Gueswendé</style></author><author><style face="normal" font="default" size="100%">Micheal Kofi Boachie</style></author><author><style face="normal" font="default" size="100%">Lilian Mburu</style></author><author><style face="normal" font="default" size="100%">Milka Wanjohi</style></author><author><style face="normal" font="default" size="100%">Richard E Sanya</style></author><author><style face="normal" font="default" size="100%">Aisha Moolla</style></author><author><style face="normal" font="default" size="100%">Veronica Ojiambo</style></author><author><style face="normal" font="default" size="100%">Petronell Kruger</style></author><author><style face="normal" font="default" size="100%">Stefanie Vandevijvere</style></author><author><style face="normal" font="default" size="100%">Gershim Asiki</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">The economic burden of type 2 diabetes on the public healthcare system in Kenya: a cost of illness study</style></title><secondary-title><style face="normal" font="default" size="100%">BMC Health Serv Res</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Adult</style></keyword><keyword><style  face="normal" font="default" size="100%">Cost of Illness</style></keyword><keyword><style  face="normal" font="default" size="100%">Diabetes Mellitus, Type 2</style></keyword><keyword><style  face="normal" font="default" size="100%">Female</style></keyword><keyword><style  face="normal" font="default" size="100%">health care costs</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">KENYA</style></keyword><keyword><style  face="normal" font="default" size="100%">Male</style></keyword><keyword><style  face="normal" font="default" size="100%">middle aged</style></keyword><keyword><style  face="normal" font="default" size="100%">prevalence</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2024 Oct 14</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">24</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;&lt;b&gt;BACKGROUND: &lt;/b&gt;The burden of chronic non-communicable diseases (NCDs) is a growing public health concern. The availability of cost-of-illness data, particularly public healthcare costs for NCDs, is limited in Sub-Saharan Africa (SSA), yet such data evidence is needed for policy action.&lt;/p&gt;

&lt;p&gt;&lt;b&gt;OBJECTIVE: &lt;/b&gt;The objective of this study was to estimate the economic burden of type 2 diabetes (T2D) on Kenya's public healthcare system in 2021 and project costs for 2045.&lt;/p&gt;

&lt;p&gt;&lt;b&gt;METHODS: &lt;/b&gt;This was a cost-of-illness study using the prevalence-based bottom-up costing approach to estimate the economic burden of T2D in the year 2021. We further conducted projections on the estimated costs for the year 2045. The costs were estimated corresponding to the care, treatment, and management of diabetes and some diabetes complications based on the primary data collected from six healthcare facilities in Nairobi and secondary costing data from previous costing studies in low and middle-income countries (LMICs). The data capture and costing analysis were done in Microsoft Excel 16, and sensitivity analysis was conducted on all the parameters to estimate the cost changes.&lt;/p&gt;

&lt;p&gt;&lt;b&gt;RESULTS: &lt;/b&gt;The total cost of managing T2D for the healthcare system in Kenya was estimated to be US$ 635&amp;nbsp;million (KES 74,521&amp;nbsp;million) in 2021. This was an increase of US$ 2&amp;nbsp;million (KES 197&amp;nbsp;million) considering the screening costs of undiagnosed T2D in the country. The major cost driver representing 59% of the overall costs was attributed to T2D complications, with nephropathy having the highest estimated costs of care and management (US$ 332&amp;nbsp;million (KES 36, 457&amp;nbsp;million). The total cost for T2D was projected to rise to US$ 1.6&amp;nbsp;billion (KES 177&amp;nbsp;billion) in 2045.&lt;/p&gt;

&lt;p&gt;&lt;b&gt;CONCLUSION: &lt;/b&gt;This study shows that T2D imposes a huge burden on Kenya's healthcare system. There is a need for government and societal action to develop and implement policies that prevent T2D, and appropriately plan care for those diagnosed with T2D.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">1</style></issue></record></records></xml>